| Active substance | Zidesamtinib |
| Holder | Nuvalent, Inc. |
| Status | Running |
| Indication | Treatment of patients with advanced ROS1 fusion-positive non-small cell lung cancer (ROS1+ NSCLC) who have previously received ≥ 1 prior ROS1 tyrosine kinase inhibitor (TKI) |
| Public documents | |
| Information for the patient | |
| Last update | 24/08/2026 |